Cannabis Science Inc (OTCMKTS:CBIS) a U.S. firm specializing in cannabis formulation-based medications development reported the appointment of renowned epidemiologist, public health physician and scholar Allen A. Herman, M.B., Ch.B., Ph.D. as the Chief Medical Officer of company. Dr. Herman is already a member of the company’s Scientific Advisory Board.
Cannabis Science reported that Dr. Herman served as a program director and project officer at the National Institute of Health. For his work in child and maternal health, he received the NIH’s Award of Merit. Dr. Herman planned the basis for a countrywide infant mortality reduction measure and served as the co-director of joint ventures between the CDC and NIH.
His performance in the project of NIH Infant Mortality Reduction research plan laid the basis for the prevailing community-based child and maternal health work designed to deliver a healthy beginning for families. Additionally, he was a member of the renowned World Mental Health Survey team. He also helped plan, execute, publish and analysis peer-reviewed scientific papers from the largest mental health survey unit in Africa, known as South African Stress and Health Study.
Dr. Herman will report to Cannabis Science President and CEO, Raymond C. Dabney to help him in numerous ways. He will work with the Scientific Advisory Board and drug development leaders. Dr. Herman will assist Mr. Dabney in the management of the expanding portfolio of international drug development plans of company.
This work will involve the advancement of a robust and secure template for drug advancement that will ensure that effectiveness, safety, and efficacy of new drugs achieve the levels set by the US FDA, and other drug regulatory bodies in Europe, Canada, and other critical regions.
Cannabis Science Inc (OTCMKTS:CBIS) suffered a sharp decline yesterday as it finished the last trading session with a loss of 8.23%. The volume surged to 7.4 million, slightly higher than the daily average of 5.7 million but not considerably high enough to mark it as a capitulation yet. Actually the volume pattern indicates a major correction going on instead of any real bear attack and increases the probability of the price moving sideways for the next few weeks in the range of $0.025-$0.045, as shown on the chart attached. The sharp intraday recovery seen yesterday keeps the possibility of an immediate bounce alive.